Bulk Inquiry
MGL-3196
- VIA-3196 - Resmetirom
- Soluble in DMSO
- MF: C17H12Cl2N6O4
- MW: 435.22
Description
Oral, liver-targeted, selective thyroid hormone receptor β-agonist (EC50 value 0.21 µM for THR-β) that is being developed for the treatment of dyslipidemia. MGL-3196 is 28-fold selective for THR-β over THR-α in an in vitro functional coactivator recruitment assay.
More Information
| Parent CAS No. | 920509-32-6 |
|---|---|
| Chemical Name | 2-(3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile |
| SMILES | N1=C(C#N)C(=O)NC(=O)N1C1=CC(Cl)=C(OC2=NNC(=O)C(C(C)C)=C2)C(Cl)=C1 |
| MFCD | N.A. |
| InChi | InChI=1S/C17H12Cl2N6O4/c1-7(2)9-5-13(22-23-15(9)26)29-14-10(18)3-8(4-11(14)19)25-17(28)21-16(27)12(6-20)24-25/h3-5,7H,1-2H3,(H,23,26)(H,21,27,28) |
| InChiKey | FDBYIYFVSAHJLY-UHFFFAOYSA-N |
| CID | 15981237 |
| Short Description | THR-β agonist |
References
- MJ Kelly et al. Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective THR-β agonist....J Med Chem. 2014 May 22;57(10):3912-23.
- R Taub et al. Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist. Atherosclerosis. 2013 Oct;230(2):373-80.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 2043 | Atorvastatin calcium |
From $66.00 |
| 2047 | Torcetrapib |
From $121.00 |
| 2152 | PX 20350 |
From $115.50 |
| 2216 | CP 346086 |
From $154.00 |
| 2286 | Evacetrapib |
From $137.50 |
| 2296 | (S)-Crizotinib |
From $93.50 |
| 2357 | LXR 623 |
From $104.50 |
| 2363 | GSK 2033 |
From $115.50 |
| 2506 | BMS 303141 |
From $99.00 |
| 4126 | Sobetirome |
From $99.00 |
Other Categories
Are you sure you would like to remove this item from the shopping cart?
This item is a part of the approved quote. Removing it will remove all quote items from the cart.